Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

4D Pharma plc. (10/8/19). "Press Release: 4D Pharma Collaborates with MSD to Develop Live Biotherapeutics for Vaccines".

Organisations Organisation 4D Pharma plc (AIM: DDDD)
  Group 4D Pharma (Group)
  Organisation 2 Merck & Co. Inc. (NYSE: MRK)
  Group Merck (US) (MSD) (Group)
Products Product microbiomic treatment (live biotherapeutic product, LBP)
  Product 2 vaccine
Index term Index term Merck (US)–4D Pharma: microbiomic treatments, 201910– collab r+d Live Biotherapeutics as vaccines
Persons Person Peyton, Duncan Joseph (4D Pharma 201602 CEO + major shareholder)
  Person 2 Wilson, Dominic (Bryan Garnier 201709– Managing Director at European Healthcare division before Zeus Capital + Nomura)
     


4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics (“LBPs”) for vaccines.

Under the terms of the agreement 4D’s proprietary MicroRx® platform will be paired with MSD’s expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications. 4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration. In addition to an upfront cash payment, for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration. MSD will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options.

Duncan Peyton, 4D’s Chief Executive Officer, commented: “This research collaboration agreement brings together 4D’s innovation in the microbiome space and MSD’s track record of developing cutting-edge vaccines. MSD and 4D have worked closely combining world leading science to develop a workplan to advance the understanding of this field, with the aim of generating a new class of vaccines in areas of high unmet need.”

Daria Hazuda, Chief Scientific Officer of MSD’s Exploratory Science Center and MSD’s Vice President of Infectious Diseases and Vaccines Discovery Research, commented: “A key element of our focus in the Exploratory Science Center is the evaluation of emerging new areas of biology that have the potential to offer major beneficial impact to human health. By applying 4D’s MicroRx® technology we hope to gain meaningful insights into the role for the host microbiome in modulating the immune response and ultimately protection conferred by vaccines.”


For further information please contact:

4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130

N+1 Singer - Nominated Adviser and Joint Broker +44 (0) 20 7496 3000
Aubrey Powell/ Justin McKeegan/ Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson /Phil Walker


About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.? 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.? 4D’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.? The Company has four clinical studies in progress, namely a Phase II clinical study of Blautix in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours and a Phase I/II study of MRx-4DP0004 in asthma. Other focus programmes include disease areas such as CNS disease.

For more information, refer to https://www.4dpharmaplc.com/

   
Record changed: 2019-10-17

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for 4D Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top